A parallel approach is being evaluated in a separate trial (NCT04814004) using CD19-CAR-iNKTs armored with IL-15 in patients with acute lymphoblastic leukemia, B-cell lymphoma, or chronic lymphocytic leukemia, though results from this study have not yet been reported. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.